|
2014 Conference Publication Assessment of long course chemoradiotherapy (Lccrt) in regards to completion of chemotherapy. The experience of a tertiary referral hospitalChristie, Hayden, Burge, Matthew, Eastgate, Melissa and Wyld, David (2014). Assessment of long course chemoradiotherapy (Lccrt) in regards to completion of chemotherapy. The experience of a tertiary referral hospital. COSA's 41st Annual Scientific Meeting. Joining Forces - Accelerating Progress, Melbourne, Australia, 2-4 December, 2014. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12305 |
|
2013 Journal Article The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimatesKiely, Belinda E., Martin, Andrew J., Tattersall, Martin H. N., Nowak, Anna K., Goldstein, David, Wilcken, Nicholas R. C., Wyld, David K., Abdi, Ehtesham A., Glasgow, Amanda, Beale, Philip J., Jefford, Michael, Glare, Paul A. and Stockler, Martin R. (2013). The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates. Journal of Clinical Oncology, 31 (28), 3565-3572. doi: 10.1200/JCO.2012.44.7821 |
|
2013 Conference Publication Pancreatic cancer patient's moderate or high unmet supportive care needs over time and risk factors of future unmet needsBeesley, Vanessa L., Janda, Monika, Wockner, Leesa F., O'Rourke, Peter, Gooden, Helen, Goldstein, David, Merrett, Neil D., Wyld, David K. and Neale, Rachel E. (2013). Pancreatic cancer patient's moderate or high unmet supportive care needs over time and risk factors of future unmet needs. COSA's 40th Annual Scientific Meeting. Cancer Care Coming of Age, Adelaide Convention Centre, Adelaide, SA Australia, 12-14 November 2013. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. |
|
2013 Journal Article Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - A population-based studyJordan, S., Steer, C., DeFazio, A., Quinn, M., Obermair, A., Friedlander, M., Francis, J., O'Brien, S., Goss, G., Wyld, D. and Webb, P. (2013). Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - A population-based study. Gynecologic Oncology, 129 (2), 310-317. doi: 10.1016/j.ygyno.2013.02.007 |
|
2012 Conference Publication Pulmonary Embolism in Medical Oncology Patients: Symptomatic Versus IncidentalThaker, D. A., Blazak, J., Wyld, D., Steinke, K., Hughes, B. and Burge, M. (2012). Pulmonary Embolism in Medical Oncology Patients: Symptomatic Versus Incidental. HOBOKEN: WILEY-BLACKWELL. |
|
2012 Journal Article Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trialNeoptolemos, John P., Moore, Malcolm J., Cox, Trevor F., Valle, Juan W., Palmer, Daniel H., McDonald, Alexander C., Carter, Ross, Tebbutt, Niall C., Dervenis, Christos, Smith, David, Glimelius, Bengt, Charnley, Richard M., Lacaine, François, Scarfe, Andrew G., Middleton, Mark R., Anthoney, Alan, Ghaneh, Paula, Halloran, Christopher M., Lerch, Markus M., Oláh, Attila, Rawcliffe, Charlotte L., Verbeke, Caroline S., Campbell, Fiona, Büchler, Markus W., European Study Group for Pancreatic Cancer and Wyld, David (2012). Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA, 308 (2), 147-56. doi: 10.1001/jama.2012.7352 |
|
2012 Journal Article Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2Kirchhoff, Tomas, Gaudet, Mia M., Antoniou, Antonis C., McGuffog, Lesley, Humphreys, Manjeet K., Dunning, Alison M., Bojesen, Stig E., Nordestgaard, Borge G., Flyger, Henrik, Kang, Daehee, Yoo, Keun-Young, Noh, Dong-Young, Ahn, Sei-Hyun, Dork, Thilo, Schuermann, Peter, Karstens, Johann H., Hillemanns, Peter, Couch, Fergus J., Olson, Janet, Vachon, Celine, Wang, Xianshu, Cox, Angela, Brock, Ian, Elliott, Graeme, Reed, Malcolm W. R., Burwinkel, Barbara, Meindl, Alfons, Brauch, Hiltrud, Hamann, Ute ... Wyld, David (2012). Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. Plos One, 7 (6) e35706, e35706-1-e35706-10. doi: 10.1371/journal.pone.0035706 |
|
2012 Conference Publication Usefulness of medical oncologists' estimates of survival time in people with advanced cancerKiely, Belinda E., Martin, Andrew J., Tattersall, Martin H. N., Nowak, Anna K., Goldstein, David, Wilcken, Nicholas, Wyld, David, Beale, Philip James, Jefford, Michael, Glasgow, Amanda L., Abdi, Ehtesham A., Glare, Paul A. and Stockler, Martin R. (2012). Usefulness of medical oncologists' estimates of survival time in people with advanced cancer. 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 1-6 June 2012. Alexandria, VA USA: American Society of Clinical Oncology. |
|
2012 Conference Publication Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, kShapiro, Jeremy David, Siu, Lillian L., O'Callaghan. Christopher J., Zalcberg, John Raymond, Moore, Malcolm J., Price, Timothy Jay, Doyle, Catherine, Simes, John, Findlay, Brian Peter, Cronk, Michelle F., Shaikh, Asif, Joubert, Warren Lance, Samson, Benoit, Bonaventura, Antonino, Underhill, Craig, Wyld, David, Walters, Ian B., Phillips, Penny, Tu, Dongsheng and Jonker, Derek J. (2012). Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, k. 2012 ASCO Annual Meeting, Chicago Il, United States, 01-05 June 2012. Alexandria, VA United States: American Society of Clinical Oncology. |
|
2012 Conference Publication Treatment of metastatic neuroendocrine tumours with (Lu)-L-177-octreotate: experience at Royal Brisbane and Women's HospitalSharma, A., Burge, M., MacFarlane, D., McDade, H., Kemp, S. and Wyld, D. (2012). Treatment of metastatic neuroendocrine tumours with (Lu)-L-177-octreotate: experience at Royal Brisbane and Women's Hospital. Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, Program and Abstracts: Targeting Cancer from Diagnosis to Cure & 5th Annual COGNO Annual Scientific Meeting , Brisbane, QLD, Australia, 8 – 10 August 2012. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. |
|
2012 Conference Publication Safety of bevacizumab used in routine practice in patients with metastatic colorectal cancerDzienis, M., Malczewski, A., Goh, J., Hughes, B., Eastgate, M., Wyld, D. and Burge, M. (2012). Safety of bevacizumab used in routine practice in patients with metastatic colorectal cancer. Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, Program and Abstracts: Targeting Cancer from Diagnosis to Cure & 5th Annual COGNO Annual Scientific Meeting, Brisbane, QLD Australia, 8-10 August 2012. Wiley-Blackwell Publishing. |
|
2012 Journal Article The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopauseChirgwin, Jacquie, Sun, Zhuoxin, Smith, Ian, Price, Karen N., Thuerlimann, Beat, Ejlertsen, Bent, Bonnefoi, Herve, Regan, Meredith M., Goldhirsch, Aron, Coates, Alan S., International Breast Cancer Study Group (IBCSG) and Wyld, David (2012). The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Research and Treatment, 131 (1), 295-306. doi: 10.1007/s10549-011-1741-6 |
|
2011 Journal Article Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyPavel, Marianne E., Hainsworth, John D., Baudin, Eric, Peeters, Marc, Hörsch, Dieter, Winkler, Robert E., Klimovsky, Judith, Lebwohl, David, Jehl, Valentine, Wolin, Edward M., Öberg, Kjell, Van Cutsem, Eric, Yao, James C., RADIANT-2 Study Group and Wyld, D. (2011). Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. The Lancet, 378 (9808), 2005-2012. doi: 10.1016/S0140-6736(11)61742-X |
|
2011 Journal Article Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: A pilot studyNewton, Melissa J ., Hayes, Sandi C., Janda, Monika, Webb, Penelope M., Obermair, Andreas, Eakin, Elizabeth G., Wyld, David, Gordon, Louisa G. and Beesley, Vanessa L. (2011). Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: A pilot study. BMC Cancer, 11 (1) 389, 389-1-389-9. doi: 10.1186/1471-2407-11-389 |
|
2011 Journal Article Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancerRegan, Meredith M, Price, Karen N, Giobbie-Hurder, Anita, Thürlimann, Beat, Gelber, Richard D, International Breast Cancer Study Group and BIG 1-98 Collaborative Group, Colosimo, M., Cheuk, R., Kenny, L., McCarthy, N. and Wyld, D. (2011). Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast cancer research : BCR, 13 (3) 209, 209. doi: 10.1186/bcr2837 |
|
2011 Journal Article Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinomaObermair, Andreas, Mileshkin, Linda, Bolz, Katharina, Kondalsamy-Chennakesavan, Srinivas, Cheuk, Robyn, Vasey, Paul, Wyld, David, Goh, Jeffrey, Nicklin, James L., Perrin, Lewis C., Sykes, Peter and Janda, Monika (2011). Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma. Gynecologic Oncology, 120 (2), 179-184. doi: 10.1016/j.ygyno.2010.10.039 |
|
2011 Conference Publication Does the addition of FDG-PET to the standard pre-operative work up of pancreatic cancer change management - a prospective studyBurge, M., Houston, K. E., Francesconi, A., O'Rourke, N., Lee, J., Macfarlane, D., Wyld, D., Hopkins, G., Finch, R. and Nathanson, L. (2011). Does the addition of FDG-PET to the standard pre-operative work up of pancreatic cancer change management - a prospective study. European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011. Elsevier: Oxford, United Kingdom. |
|
2010 Journal Article Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patientsBeesley, Vanessa L., Clavarino, Alexandra M., Webb, Penelope M., Wyld, David K., Francesconi, Alessandra B., Horwood, Keith R., Doecke, James D., Loos, Colleen A. and Green, Adele C. (2010). Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients. Supportive Care in Cancer, 18 (8), 943-949. doi: 10.1007/s00520-009-0734-z |
|
2010 Journal Article Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agentLickliter, J. D., Francesconi, A. B., Smith, G., Burge, M., Coulthard, A., Rose, S., Griffin, M., Milne, R., McCarron, J., Yeadon, T., Wilks, A., Cubitt, A., Wyld, D. K. and Vasey, P. A. (2010). Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. British Journal of Cancer, 103 (5), 597-606. doi: 10.1038/sj.bjc.6605841 |
|
2010 Journal Article Medical costs and outcomes for Australian women with ovarian cancer: A patient-level analysis over 2.5 yearsGordon, Louisa G., Scuffham, Paul A., Beesley, Vanessa L., Green, Adele C., DeFazio, Anna, Wyld, David K., Clavarino, Alexandra M., Australian Ovarian Cancer Study Group and Webb, Penelope M. (2010). Medical costs and outcomes for Australian women with ovarian cancer: A patient-level analysis over 2.5 years. International Journal of Gynecological Cancer, 20 (5), 757-765. doi: 10.1111/IGC.0b013e3181dbd13f |
